🍬 Type 2 Diabetes Glucose-Lowering Pathway (comorbidity-driven drug choice)
This tool selects the preferred glucose-lowering add-on for type 2 diabetes by comorbidity, layering SGLT2 inhibitors and GLP-1 receptor agonists onto metformin per Chinese T2DM guidelines and the ADA.
Cardiorenal-protective agents are chosen for the comorbidity even when HbA1c is at target — the indication is organ protection, not just glucose control. (original synthesis · not guideline verbatim)
Paste the link in Slack, Teams, X, or LinkedIn — the preview image comes from this page’s Open Graph card.
When to use
Use when escalating T2DM therapy: comorbid heart failure or CKD favors an SGLT2i, ASCVD or high cardiovascular risk favors a GLP-1RA or SGLT2i, and the absence of these favors individualized dual therapy.
How it works
Decision logic: heart failure/CKD → SGLT2i (GLP-1RA if eGFR < 30); ASCVD/high risk → GLP-1RA or SGLT2i regardless of HbA1c; otherwise individualized add-on by hypoglycemia risk, weight, and cost.
Key points
- Cardiorenal-protective agents are chosen for the comorbidity even when HbA1c is at target — the indication is organ protection, not just glucose control. (original synthesis · not guideline verbatim)
- At eGFR < 30 most SGLT2i are off-label, so a GLP-1RA becomes the preferred cardiorenal add-on.
- Metformin and lifestyle remain the foundation unless contraindicated.
References
- Chinese Diabetes Society. Guideline for the Prevention and Treatment of Type 2 Diabetes in China (2020 edition).
- American Diabetes Association. Standards of Care in Diabetes — Pharmacologic Approaches to Glycemic Treatment.
Worked calculation
The values below come from this tool's own example placeholders and are computed server-side with the formula shown on this page, so the arithmetic can be checked quickly. It demonstrates how to substitute values only — it is not clinical advice and not a real case.
| Comorbid ASCVD or high cardiovascular risk | Yes |
|---|---|
| Comorbid heart failure | Yes |
| Comorbid chronic kidney disease (CKD) | Yes |
| eGFR (optional, for SGLT2i applicability) | 60 mL/min/1.73m² |
→Preferred add-onPreferred SGLT2i
- Comorbidities：ASCVD/high-risk, heart failure, CKD
- Base therapy：Lifestyle intervention + metformin (continued unless contraindicated)
- Preferred add-on：Preferred SGLT2i
| Comorbid ASCVD or high cardiovascular risk | No |
|---|---|
| Comorbid heart failure | No |
| Comorbid chronic kidney disease (CKD) | No |
| eGFR (optional, for SGLT2i applicability) | 60 mL/min/1.73m² |
→Preferred add-onIndividualized dual therapy
- Comorbidities：none
- Base therapy：Lifestyle intervention + metformin (continued unless contraindicated)
- Preferred add-on：Individualized dual therapy
Frequently asked questions
- What is Type 2 Diabetes Glucose-Lowering Pathway (comorbidity-driven drug choice)?
- This tool selects the preferred glucose-lowering add-on for type 2 diabetes by comorbidity, layering SGLT2 inhibitors and GLP-1 receptor agonists onto metformin per Chinese T2DM guidelines and the ADA.
- How is Type 2 Diabetes Glucose-Lowering Pathway (comorbidity-driven drug choice) calculated? What is the core formula?
- Decision logic: heart failure/CKD → SGLT2i (GLP-1RA if eGFR < 30); ASCVD/high risk → GLP-1RA or SGLT2i regardless of HbA1c; otherwise individualized add-on by hypoglycemia risk, weight, and cost.
- When is Type 2 Diabetes Glucose-Lowering Pathway (comorbidity-driven drug choice) used?
- Use when escalating T2DM therapy: comorbid heart failure or CKD favors an SGLT2i, ASCVD or high cardiovascular risk favors a GLP-1RA or SGLT2i, and the absence of these favors individualized dual therapy.
- What are the key clinical points for Type 2 Diabetes Glucose-Lowering Pathway (comorbidity-driven drug choice)?
- Cardiorenal-protective agents are chosen for the comorbidity even when HbA1c is at target — the indication is organ protection, not just glucose control. (original synthesis · not guideline verbatim) At eGFR < 30 most SGLT2i are off-label, so a GLP-1RA becomes the preferred cardiorenal add-on. Metformin and lifestyle remain the foundation unless contraindicated.
- What are the limits and cautions when using Type 2 Diabetes Glucose-Lowering Pathway (comorbidity-driven drug choice)?
- For licensed clinicians and clinical researchers. Interpret results with history, investigations and local protocols; not a diagnosis or prescription, and not a substitute for multidisciplinary decision-making or local guidelines.
- How is Type 2 Diabetes Glucose-Lowering Pathway (comorbidity-driven drug choice) calculated in practice? Can you show a worked example?
- Inputs: Comorbid ASCVD or high cardiovascular risk Yes, Comorbid heart failure Yes, Comorbid chronic kidney disease (CKD) Yes, eGFR (optional, for SGLT2i applicability) 60 mL/min/1.73m² → Result: Preferred add-on Preferred SGLT2i（Comorbidities: ASCVD/high-risk, heart failure, CKD, Base therapy: Lifestyle intervention + metformin (continued unless contraindicated), Preferred add-on: Preferred SGLT2i） Inputs: Comorbid ASCVD or high cardiovascular risk No, Comorbid heart failure No, Comorbid chronic kidney disease (CKD) No, eGFR (optional, for SGLT2i applicability) 60 mL/min/1.73m² → Result: Preferred add-on Individualized dual therapy（Comorbidities: none, Base therapy: Lifestyle intervention + metformin (continued unless contraindicated), Preferred add-on: Individualized dual therapy）